Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                Web Page URLs for STN Seminar Schedule - N. America
NEWS 1
NEWS 2 Apr 08
                "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22
                Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22
                BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22
                Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03
                New e-mail delivery for search results now available
                MEDLINE Reload
NEWS 10 Jun 10
        Jun 10
NEWS 11
                PCTFULL has been reloaded
NEWS 12 Jul 02
                FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22
                USAN to be reloaded July 28, 2002;
                saved answer sets no longer valid
NEWS 14
       Jul 29
                Enhanced polymer searching in REGISTRY
                NETFIRST to be removed from STN
NEWS 15
        Jul 30
        Aug 08
                CANCERLIT reload
NEWS 16
NEWS 17
        Aug 08
                PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18
        Aug 08
                NTIS has been reloaded and enhanced
NEWS 19
        Aug 19
                Aquatic Toxicity Information Retrieval (AQUIRE)
                now available on STN
NEWS 20
                IFIPAT, IFICDB, and IFIUDB have been reloaded
       Aug 19
NEWS 21 Aug 19
                The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26
                Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03
                JAPIO has been reloaded and enhanced
NEWS 24
        Sep 16
                Experimental properties added to the REGISTRY file
NEWS 25 Sep 16
                CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01
                CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21
                EVENTLINE has been reloaded
                BEILSTEIN adds new search fields
NEWS 28 Oct 24
NEWS 29 Oct 24
                Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25
                MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18
                DKILIT has been renamed APOLLIT
                More calculated properties added to REGISTRY
NEWS 32 Nov 25
NEWS 33 Dec 02
                TIBKAT will be removed from STN
NEWS 34 Dec 04
                CSA files on STN
        Dec 17
                PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 35
NEWS 36
        Dec 17
                TOXCENTER enhanced with additional content
NEWS 37
        Dec 17
                Adis Clinical Trials Insight now available on STN
NEWS 38
       Dec 30
                ISMEC no longer available
NEWS 39
        Jan 13
                Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40
        Jan 21
                NUTRACEUT offering one free connect hour in February 2003
NEWS 41
                PHARMAML offering one free connect hour in February 2003
        Jan 21
NEWS 42 Jan 29
                Simultaneous left and right truncation added to COMPENDEX,
```

ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:41:10 ON 29 JAN 2003

=> FIL REGISTRY
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:41:17 ON 29 JAN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5 DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST ENTRY 27.30

SESSION

27.51

FILE 'BIOSIS' ENTERED AT 18:42:17 ON 29 JAN 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 18:42:17 ON 29 JAN 2003

FILE 'CAPLUS' ENTERED AT 18:42:17 ON 29 JAN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 18:42:17 ON 29 JAN 2003 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 18:42:17 ON 29 JAN 2003 COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 18:42:17 ON 29 JAN 2003 COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 18:42:17 ON 29 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:42:17 ON 29 JAN 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 18:42:17 ON 29 JAN 2003 COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s 11

'SQSP' IS NOT A VALID FIELD CODE

- 'SQSP' IS NOT A VALID FIELD CODE
- 'SQSP' IS NOT A VALID FIELD CODE L2 3 L1

=> d 12 py pn au ti so ab

- L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
- PY 2001
- AU Roberge, Martin; Santell, Lydia; Dennis, Mark S.; Eigenbrot, Charles; Dwyer, Mary A.; Lazarus, Robert A.
- TI A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors
- SO Biochemistry (2001), 40(32), 9522-9531 CODEN: BICHAW; ISSN: 0006-2960
- An ew inhibitory peptide binding exosite on the protease domain of coagulation Factor VIIa (FVIIa) has been identified. A novel series of peptide inhibitors of FVIIa, termed the "A-series" peptides, identified from peptide phage libraries and exemplified by peptide A-183, specifically bind at a site that is distinct from both the active site and the exosite of another recently described peptide inhibitor of FVIIa, E-76. Peptide A-183 prolonged TF-dependent clotting in human, but not rabbit plasma. Thus, a panel of human FVIIa mutants, contg. 70 of the 76 rabbit sequence differences in the protease domain, localized the binding site to residues in the 60s loop and the C-terminus. The location of the exosite was refined by a series of FVIIa alanine mutants, which showed that proximal residues Trp 61 and Leu 251 were crit. for binding. Kinetic and equil. binding consts. for zymogen FVII, FVIIa and TF.cntdot.FVIIa

were detd. using immobilized N-terminal biotinylated A-183 by surface plasmon resonance. No peptide binding to nine other human serine proteases was obsd. Key residues on the peptide were detd. from binding to FVIIa and inhibition of FX activation using a series of alanine mutants of A-183 fused to the Z domain of protein A. Anal. of the mutagenesis data is presented in the context of a crystal structure of A-183 in complex with a version of zymogen FVII. The shape and proximity of this exosite to the active site may lend itself towards the design of new anticoagulants that inhibit FVIIa.

- \Rightarrow d 12 py pn au ti so ab 2-3
- L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
- PY 2001
- AU Dennis, Mark S.; Roberge, Martin; Quan, Cliff; Lazarus, Robert A.
- TI Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa
- SO Biochemistry (2001), 40(32), 9513-9521 CODEN: BICHAW; ISSN: 0006-2960
- A new series of peptide inhibitors of human Factor VIIa (FVIIa) has been AΒ identified and affinity matured from naive and partially randomized peptide phage libraries selected against the immobilized tissue factor.cntdot.Factor VIIa (TF.cntdot.FVIIa) complex. These "A-series" peptides contain a single disulfide bond and a 13-residue minimal core required for maximal affinity. They are exemplified by peptide A-183 (EEWEVLCWTWETCER), which binds at a newly identified exosite on the FVIIa protease domain, described in the accompanying report [Roberge, M., Santell, L., Dennis , M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R. A. (2001) Biochem. 40, XXXXX-XXXXX]. A-183 was obtained from a trypsin digest of A-100-Z, a recombinant protein comprising A-183 and the Z domain of protein A. Surprisingly, A-183 was a very potent inhibitor of TF.cntdot.FVIIa, inhibiting activation of Factor X (FX) and Factor IX and amidolytic activity of Chromozym t-PA with IC50 values of 1.6 .+-. 1.2, 3.5 + 0.3, and 8.5 + 0.3. Minetic anal. revealed that A-183 was a partial (hyperbolic) mixed-type inhibitor of FX activation having a Ki of 200 pM as well as a partial competitive inhibitor of amidolytic activity. The A-series peptides were also specific and potent inhibitors of TF-dependent clotting as measured in a prothrombin time (PT) clotting assay and had no effect on the TF-independent activated partial thromboplastin time. At satg. concns. of peptide, the maximal extent by which A-183 and A-100-Z inhibited the rate of FX activation was $78 \cdot +-. 3$ and 89 .+-. 6%, resp. The degree of inhibition of the rate of FX activation correlated with a max. fold prolongation in the PT assay of 1.8-fold for A-183 and 3.3-fold for A-100-Z. The A-series peptides represent a new class of peptide exosite inhibitors that are capable of attenuating, rather than completely inhibiting, the activity of TF.cntdot.FVIIa, potentially leading to anticoagulants with an increased therapeutic window.
- L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
- PY 2001

2002

PATENT NO. KIND DATE

- PI WO 2001010892 A2 20010215 EP 1203014 A2 20020508
- IN Dennis, Mark S.
- TI Factor VIIa antagonists for diagnostic or therapeutic use
- SO PCT Int. Appl., 80 pp.

09921880

CODEN: PIXXD2

This invention provides novel compds. which prevent or block a FVIIa mediated or assocd. process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compds. of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the assocn. of FVII or FVIIa with a peptide compd. of the present invention. The invention also provides pharmaceutical compns. comprising the novel compds. as well as their use in diagnostic, therapeutic, and prophylactic methods.